Chip Somodevilla/Getty Images

GOP congressman Chris Collins will plead guilty in an insider-trading case, Bloomberg reported Monday, citing court documents and sources close to the matter.

The House Representative for New York's 27th District first pled not guilty after being arrested in 2018.

His son, Cameron Collins, and the father of Cameron's fiancee, Stephen Zarsky, were also arrested, and changed their pleas with the representative.

The trial is tentatively scheduled for February 2020.

Collins submitted his resignation letter to House Speaker Nancy Pelosi and New York Governor Andrew Cuomo Monday afternoon.

Visit the Business Insider homepage for more stories.

GOP congressman Chris Collins of New York's 27th District will plead guilty to insider trading, Bloomberg reported Monday morning, citing court documents and sources close to the case.

Collins submitted his letter of resignation to House Speaker Nancy Pelosi and New York Governor Andrew Cuomo Monday afternoon. The resignation will go into effect Tuesday.

The GOP congressman was charged with trading on non-public knowledge on Innate Immunotherapeutics, an Australian biotech firm. Collins was arrested in August 2018 with his son, Cameron Collins, along with the father of Cameron's fiancee, Stephen Zarsky.

All three first pled not guilty to the crimes, but Cameron and Zarsky will change their pleas with the congressman, Bloomberg reported. Collins' change-of-plea hearing is set for 3 p.m. ET Tuesday in Manhattan federal court, while Cameron and Zarsky's hearings are scheduled for 2 p.m. ET Thursday.

Read more: Wall Street titans including JPMorgan and Pimco are flagging a striking disconnect in markets that exposes how worried investors are about another crash

Chris Collins served on the Innate's board and called his son with a stock tip after the company failed a key drug test, prosecutors claimed. Cameron then sold shares of the company and passed the information on to Zarsky, who also unloaded shares, according to the complaint.

The trades occurred before news of the failed trial was made public, prosecutors alleged. Innate stock dropped 92% on the Australian Securities Exchange after the public announcement of the drug's failed test.

Lawyers for Collins could not be immediately reached.

Now read more markets coverage from Markets Insider and Business Insider:

JPMorgan predicts Apple's stock will spike 20% on strong iPhone demand

The Fed is injecting hundreds of billions into markets — and it's a practice that could become the new normal

'We're being squeezed': Marketers are freaking out about coming privacy laws in the US and worry that it will be worse than Europe's GDPR

NOW WATCH: Mexico has just one store where you can legally buy a gun and it's located on a heavily-guarded military base